Lovelace awarded $20m contract with NIH to lead disease model research collaboration

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/ PATCHARIN SAENLAKON)
(Image: Getty/ PATCHARIN SAENLAKON)

Related tags: Nih, Translational medicine, translational sciences, preclinical, Preclinical contract research, preclinical development, Modeling and simulation

Lovelace Biomedical leads a collaboration with The Jackson Laboratory, Exemplar Genetics, Iontox, and the University of Pennsylvania as part of a $20m contract with the NIH.

The preclinical contract research organization​ (CRO) Lovelace will lead the four institutions to create and characterize disease models for unmet medical needs in a contract with the National Institute of Health’s (NIH) National Center for the Advancement of Translational Sciences (NCATS).

With this $20m (€17.7) contract, the group will work with the NIH to define research priorities. However, a spokesperson for Lovelace told us that it is starting immediately with a research program focused on Sickle Cell disease. According to company, this disease has been difficult to develop treatments for without the proper resources.

Lovelace stated it selected research institutions that have the capabilities to understand genetic underpinnings of diseases and study the genetic impact on diseases.

NCATS was established to accelerate translational research processes and focuses on moving treatments for genetic diseases into clinical trials. The center does so by developing resources and technologies to bypass obstacles often seen when translating developments to the clinic.

AMRI was previously awarded a contract​ with the NIH’s NCATS in 2017 to provide drug substance development and manufacturing services across pre-clinical phases of translational science.

University of Pennsylvania has worked with CROs before in manufacturing collaborations. In 2015, WuXi worked with the university to produce gene therapy vectors through its gene therapy program​ focused on developing gene vectors derived from recombinant viruses.

Related news

Show more

Related products

show more

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 05-Nov-2018 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Baxter’s Oncology Contract Manufacturing

Baxter’s Oncology Contract Manufacturing

Baxter BioPharma Solutions | 29-Aug-2018 | Product Brochure

Baxter BioPharma Solutions’ FOYA award-winning facility in Halle/Westfalen, Germany, offers state-of-the-art parenteral cGMP manufacturing at one location,...

Related suppliers

Follow us

Products

View more

Webinars